Two EGF Receptor blockers, gefitinib and erlotinib, have been demonstrated to be effective in front-line therapy in patients with inoperable NSCLC harboring EGFR-activating mutations.[6], [7] Erlotinib is also authorized after failure of previous chemotherapy and as maintenance therapy.[8], [9]. Here, EGFR is linked to non-small cell lung carcinoma.